- Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing
- By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries
- Cybin filed the PCT application to provide broad international patent protection of key intellectual property
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to focus on its goal to improve the lives of those suffering from mental illness by changing the expectation of treatment. As part of that mission, the company has filed an international patent application that would provide the potential to obtain patent coverage in 153 countries (
https://ibn.fm/Of5wi).
“Technologies gained by Cybin resulting from our strategic acquisition of Adelia Therapeutics, coupled with subsequent research initiatives from our experienced scientific team, have produced Cybin’s first PCT (Patent Cooperation Treaty) filing,” said Cybin CEO Doug Drysdale. “As we progress our R&D and clinical programs, we expect to continue to create and develop innovative therapeutics with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects.”
By filing a single international application with the Patent Cooperation Treaty (“PCT”), Cybin can simultaneously seek protection for its proprietary drug treatments in a large number of countries (
https://ibn.fm/zTFMK). In addition, the PCT assists applicants in seeking patent protection internationally for their inventions, helps patent offices with their patent-granting decisions, and facilitates public access to a wealth of technical information relating to those inventions.
Cybin filed the PCT application to provide broad international patent protection of key intellectual property in support of the company’s strategic objectives. Those objectives include the company’s three-pillar drug development strategy: creating a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; efficient drug delivery to enhance dosing control; and a potential novel treatment regimen.
Specifically, the company is working on four drug programs: CYB001, a sublingual psilocybin formulation designed for patients suffering from major depressive disorder; CYB003 and CYB004, both proprietary deuterated psychedelic tryptamines designed for treatment of alcohol-use disorder and other therapy-resistant psychiatric disorders; and CYB005, a phenethylamine-targeting psychiatry and neurology treatment.
Psychedelic therapies are being seriously considered as a novel treatment option for a variety of mental health issues. For decades, psychedelics have been largely ignored because both federal and state laws prohibited the substances. However, a growing body of research is showing evidence of both the efficacy and safety of psychedelic use, and public opinion about the drugs is changing. While psychedelics may feel like a new industry, they actually boast a long history of use within indigenous cultures that stretches back centuries. A paradigm shift has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, and Cybin is leading the way.
Cybin is confident that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at
www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at
https://ibn.fm/CYBN
